

# 1 **Mutation in CDC42 gene set as a response biomarker** 2 **for immune checkpoint inhibitor therapy**

3 **Kun Wang<sup>1,2,3†</sup>, Yingying Zhang<sup>1,2,3†</sup>, Zhaoming Su<sup>3</sup>, Bei Wang<sup>3</sup>, Yuanyang Zhou<sup>3</sup>, Xiaochu Tong<sup>3</sup>,**  
4 **Chengying Xie<sup>3,4</sup>, Xiaomin Luo<sup>3</sup>, Sulin Zhang<sup>3\*</sup>, Mingyue Zheng<sup>1,2,3\*</sup>**

5 <sup>1</sup> School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of  
6 China, Hefei 230026, China

7 <sup>2</sup> The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Division of Life Sciences and Medicine,  
8 University of Science and Technology of China, Hefei, 230001, China

9 <sup>3</sup> Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia  
10 Medica, Chinese Academy of Sciences; 555 Zuchongzhi Road, Shanghai 201203, China

11 <sup>4</sup> Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 393 Middle Huaxia Road,  
12 Shanghai, 201210, China

13  
14 † These authors contributed equally to this work.

15  
16 Corresponding author. M. Zheng, School of Life Sciences, Division of Life Sciences and Medicine, University of  
17 Science and Technology of China, Hefei, 230026, China. E-mail: myzheng@simm.ac.cn; S. Zhang, Drug  
18 Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,  
19 Chinese Academy of Sciences; 555 Zuchongzhi Road, Shanghai 201203, China. E-mail addresses:  
20 slzhang@simm.ac.cn.

## 22 **Abstract**

### 23 **Background**

24 Immunotherapy has proven notably effective in treating tumors across diverse patient populations. However, some  
25 patients do not respond to immune checkpoint inhibitors (ICIs). Thus, there is a need for reliable biomarkers that  
26 can predict clinical responses to ICI treatment accurately.

## 27 **Methods**

28 Our focus is on CDC42, a protein that stimulates multiple signaling pathways, promoting tumor growth. We  
29 hypothesize that its defective function may indicate a patient's response to ICI therapy. We consider CDC42, along  
30 with its downstream binding and effector proteins, as a gene set. This is because their mutation could result in  
31 defective CDC42 function. We investigated the mutations in the CDC42 gene set as a potential biomarker for  
32 clinical benefits from ICI treatment. We also examined whether the combined use of a CDC42 inhibitor and ICI  
33 could enhance the efficacy of ICI.

## 34 **Results**

35 The presence of mutations in the CDC42 gene set correlated with improved overall survival (OS:  $p = 2.9E-4$ ) and  
36 progression-free survival (PFS:  $p = 2.92E-6$ ). Furthermore, our analysis of immune response landscapes among  
37 different CDC42 gene set statuses supports its potential as a biomarker for ICI therapy. Animal experiments also  
38 revealed that combining the CDC42 inhibitor (ML141) with anti-PD-1 blockade can synergistically reduce tumor  
39 growth.

## 40 **Conclusions**

41 Our study suggests that the CDC42 gene set could serve as a novel biomarker for the clinical response to ICI  
42 treatment. This finding also provides insight into the potential of combining ICI and CDC42 inhibitor use.

43

44 **Key words:** Immunotherapy, Biomarker, CDC42, Clinical response, Pan-cancer

45

## 46 **Background**

47 Immune inhibitor therapy, such as anti-programmed cell death (ligand) 1 [PD-(L)1] and anti-cytotoxic T  
48 lymphocyte antigen 4 (CTLA-4) drugs, has been successful in cancer therapy and improving long-term survival for  
49 patients. However, the effectiveness of immune checkpoint inhibitor (ICI) drugs can vary greatly among different  
50 patients due to tumor heterogeneity. While these drugs have shown positive effects in some patients, 60%-80% of  
51 patients do not respond clinically to them[1]. Therefore, it is important to identify predictive biomarkers that can  
52 indicate patients' clinical benefit[2].

53

54 CDC42 is a type of ras homologous (rho) GTPase. Previous studies have reported that CDC42 simulates tumor  
55 genesis, progression, invasion and metastatic[3]. In a previous study by Kalim et al., it was reported that inhibiting  
56 CDC42 activity in regulatory T cells (Tregs) can enhance anti-tumor immunity[4]. While Kalim et al. report that  
57 the immuno-effect of the CD42 inhibitor outweighs any tumor cell-intrinsic effect[4], it has also been reported  
58 that a low level CDC42 in the serum can predict the clinical response to ICI in patients with advanced  
59 hepatocellular carcinoma (HCC) [5] and advanced cervical cancer[6]. Therefore, it is valuable to explore the  
60 defective function of CDC42 signaling in tumors beyond Tregs and whether it can raise the probability of a  
61 response to ICI. If the defective function of CDC42 signaling is a biomarker for ICI therapy, it could provide  
62 further insight into the combined use of ICI and CDC42 inhibitor.

63

64 The function of CDC42 in control cell growth and polarity not only depends on itself but also on its binding  
65 protein and effector protein. Therefore, we consider CDC42, its binding protein, and effector protein as a gene set  
66 and investigate their potential as a biomarker for indicating the clinical benefit of ICI therapy, i.e., explore the  
67 defectiveness of CDC42 function's biomarker role indirectly. We examine whether there is a significant difference  
68 in overall survival (OS) and progression-free survival (PFS) among patients with different CDC42 gene set  
69 statuses. And we do bootstrap based on collected ICI therapy datasets. Using the ICI therapy datasets and their

70 bootstrap samples, we assess whether the CDC42 gene set status can differentiate the clinical benefit of ICI  
71 treatment in patients. To further explain the predictive performance of the CDC42 gene set status, we examine the  
72 intrinsic and extrinsic immune response landscapes among its status. Additionally, we investigate whether the  
73 CDC42 gene set status significantly differentiates signature levels reported to influence the efficacy of ICI therapy,  
74 such as the level of CD8 T cell infiltration.

75

76 Furthermore, to validate whether defective CDC42 function can serve as a biomarker for ICI, we investigated  
77 whether ML141 could increase the survival time of mice. We selected mice with 4T1 breast carcinoma, which has  
78 been shown to be highly resistant to anti-PD-1 or anti-CTLA-4 therapy for the experiment[7]. ML141 is a  
79 selective and non-competitive inhibitor of CDC42[8], which was utilized to simulate the defective function of  
80 CDC42. Our study also aims to demonstrate the potential of CDC42 inhibitors in improving the anti-tumor effects  
81 of ICI, particularly in cases where tumors exhibit resistance to ICI therapy. Overall, our study explores the role of  
82 CDC42 gene set status as a biomarker for ICI therapy and seeks evidence to support the use of a CDC42 inhibitor  
83 to enhance the efficacy of the ICI inhibitors.

84

## 85 **Methods**

### 86 **Materials**

87 We collected nine whole exome sequencing (WES) data for biomarker discovery. The Miao2019 cohort consists  
88 of renal clear cell carcinoma patients treated with anti-PD-1 drugs[9]. The Hugo and Riaz cohorts comprise  
89 melanoma patients treated with anti-PD-1 drugs [10, 11]. The Miao2018 cohort consists of pan-cancer patients  
90 treated with either 1) anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4) drugs, 2) anti-PD-1 drugs, or 3)  
91 a combination of both anti-CTLA-4 and anti-PD-1 drugs [12]. The Rizvi cohort comprises non-small cell lung  
92 cancer (NSCLC) patients treated with anti-PD-1 drugs[13]. The Snyder and Van Allen cohorts consist of

93 melanoma patients treated with anti-CTLA-4 drugs [14, 15]. The Hellmann cohort comprises non-small cell lung  
94 cancer patients treated with both anti-CTLA-4 and anti-PD-1 drugs[16]. The Liu cohort comprises melanoma  
95 patients treated with anti-PD-1 drugs[17](see supplementary material Table S1). We downloaded eight WES  
96 datasets and corresponding clinical information from the cBioPortal database (<https://www.cbioportal.org>). The  
97 Riaz cohort was obtained from the original literature[12].

98

99 The collected data pertains to the drug response of cancer patients undergoing ICI therapy. In order to combine  
100 this data from multiple sources, we utilized the processing method described by Zhang et al[18]. Initially, we  
101 excluded three tumor types with a sample size of less than 10. We also removed 33 samples that had a  
102 non-evaluable response (NE), 7 samples that were not profiled and 7 samples classified as "OTHER  
103 CONCURRENT THERAPY". Furthermore, we eliminated 151 duplicate samples in the Miao2018 cohort. This  
104 cohort had 27 overlapping samples with the Rizvi cohort, 37 with the Snyder cohort, and 87 with the Van Allen  
105 cohort.

106

107 Table 1 summarizes the characteristics of the filtered data. The ICI therapy dataset includes five tumor types:  
108 Melanoma (n=422), Non-Small Cell Lung Cancer (128), Renal Cell Carcinoma (35), Bladder Cancer (27) and  
109 Head and Neck Cancer (10). The ICI therapy dataset includes the following types of drug treatment: anti-PD-1  
110 (306), anti-CTLA-4 (174) and anti-CTLA-4 + anti-PD-1 (142). The proportion of CDC42 gene set mutation in the  
111 ICI therapy dataset is 18%.

112

113 Furthermore, we collected data from 32 types of solid cancer data from The Cancer Genome Atlas (TCGA) to  
114 conduct further analysis on the CDC42 gene set status as a biomarker. This data includes WES data, RNA-seq  
115 data, and patients' overall survival time. The WES and RNA-seq data were obtained using TCGAbiolinks[19], and

116 the survival time data were collected from Liu et al[20]. Additionally, we obtained Cibersort immune infiltration  
117 values and TCR Shannon for each TCGA cancer sample from Thorsson et al[21].

118

119 **Table 1.** Characteristics of the ICI therapy dataset.

<b>Characteristic</b>	<b>Num (Portion)</b>
<b>Gender</b>	
Male	334 (54%)
Female	223 (36%)
NA	65 (10%)
<b>Age</b>	
<65	193 (31%)
>=65	140 (23%)
NA	289 (46%)
<b>Cancer type</b>	
Melanoma	422 (68%)
Non-Small Cell Lung Cancer	128 (20%)
Renal Cell Carcinoma	35 (6%)
Bladder Cancer	27 (4%)
Head and Neck Cancer	10 (2%)
<b>Drug target</b>	
anti-PD-1	306 (49%)
anti-CTLA-4	174 (28%)

anti-CTLA-4 + anti-PD-1 142 (23%)

**Treatment best response**

PR 136 (22%)

CR 40 (6%)

PD 259 (42%)

SD 132 (21%)

NA 55 (9%)

**Durable clinical benefit**

Benefit 240 (39%)

Nonbenefit 304 (49%)

NA 78 (12%)

**CDC42 gene set status**

Mutant 113 (18%)

Wild type 509 (82%)

**Overall patients** 622

---

120 PR: partial response. CR: complete response. PD: progressive disease. SD: stable disease. NA: not available.

121

122 **CDC42 gene set mutation definition**

123 In this study, we defined the CDC42 gene set as a set of genes that includes CDC42, CDC42 binding protein

124 kinase alpha (CDC42BPA), CDC42 binding protein kinase beta (CDC42BPB), CDC42BPG CDC42 binding

125 protein kinase gamma (CDC42BPG), CDC42 effector protein 1 (CDC42EP1), CDC42 effector protein 2

126 (CDC42EP2), CDC42 effector protein 3 (CDC42EP3), CDC42 effector protein 4 (CDC42EP4), CDC42 effector

127 protein 5 (CDC42EP5), CDC42 small effector 1 (CDC42SE1), CDC42 small effector 2 (CDC42SE2). These

128 genes are involved in CDC42 function, and their mutation may affect CDC42's signal. If any gene in this gene set  
129 undergoes a non-synonymous mutation, the CDC42 gene set status is defined as mutated, which means the  
130 defective function of CDC42 to some extent.

131

### 132 **Clinical endpoint analysis**

133 The objective response rate (ORR) was defined as the proportion of patients who received ICI therapy and  
134 achieved a complete response (CR) or partial response (PR)[22]. Durable clinical benefit (DCB) was defined as a  
135 CR, PR, or stable diseases (SD) that lasted for more than 6 months[23].

136

### 137 **Immune cell fraction analysis**

138 We obtained the leukocyte fraction from Thorsson et al[21]. The lymphocyte fractions were aggregated by using  
139 the cibersort estimate, including B cells naïve, B cells memory, T cells CD4 naïve, T cells CD4 memory resting, T  
140 cells CD4 memory activated, T cells follicular helper, Tregs, T cells gamma delta, T cells CD8, NK cells resting,  
141 NK cells activated, and Plasma cells[21]. The molecular estimate for tumor-infiltrating lymphocyte (TIL) fraction  
142 was obtained by multiplying the aggregated lymphocyte fraction from the cibersort estimate with the leukocyte  
143 fraction obtained from Thorsson et al. The estimate for TIL fraction images was obtained from Saltz et al[24].

144

### 145 **Immune signatures analysis**

146 We obtained 29 immune signatures from He et al[25] and performed single-sample gene set enrichment analysis  
147 (ssGSEA) using the "GSVA" R package[26] based on these signatures.

148

### 149 **GSEA analysis**

150 We used TCGA RNA-seq data and the DESeq2 package[27] to identify differentially expressed genes.



151 Subsequently, we conducted GSEA analysis on the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway  
152 using the clusterProfiler package[28].

153

### 154 **Estimation of cytolytic activity**

155 We estimated cytolytic activity (CYT) based on the method described by Rooney et al[29]. This involves  
156 calculating the geometric mean of granzyme A (GZMA) and perforin 1 (PRF1) expression.

157

### 158 **Mutation and neoantigens analysis**

159 For this study, we assessed tumor mutational burden (TMB) using the number of non-synonymous mutations. The  
160 data for nonsilent mutation, silent mutation, single nucleotide variation (SNV) neoantigens and indel neoantigens  
161 were obtained from Thorsson et al[21].

162

### 163 **Statistical analysis**

164 We used the two-sided Fisher's exact test to explore the difference between CDC42 gene set status and clinical  
165 benefit. To further assess the potential of CDC42 gene set as a biomarker for predicting the clinical benefits of ICI,  
166 we employed bootstrapping to generate 1000 bootstrap samples for both CDC42 gene set mutation and wild type  
167 patients. This allowed us to obtain empirical distributions for ORR and DCB[30]. Subsequently, we then  
168 compared the 95% confidence intervals of ORR and DCB based on the CDC42 gene set status. The two-sided  
169 Wilcoxon rank sum test was used to compare the TMB and neoantigen load (NAL) of ICI therapy data. We also  
170 used the two-sided Wilcoxon rank sum test to compare TCGA gene expression levels, mutation rate, neoantigens,  
171 cell fraction, immune signatures, TCR Shannon and CYT between the CDC42 gene set mutation group and the  
172 CDC42 gene set wild type group. Additionally, we plotted the KM curve of PFS and OS using the logrank test  
173 based on CDC42 gene set status, which used the  $\chi^2$  test statistic to calculate P values[31]. Fisher's exact test was

174 implemented using the python package scipy[32]. The logrank test, Cox Proportional-Hazards analysis, and  
175 Wilcoxon rank sum test were implemented using the survminer package and ggsignif package in R version 4.2.3  
176 (<https://www.r-project.org>).

177

## 178 **Animal experiment**

179 All procedures performed on animals were conducted in accordance with the Institutional Animal Care and Use  
180 Committee at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (IACUC Issue NO.  
181 2023-10-ZMY-03). For the pharmacodynamics experiment, BALB/c mice (6-8 weeks old) were purchased and  
182 inoculated subcutaneously with  $1 \times 10^6$  4T1 tumor cells into the right side of the mice's axilla. The animals were  
183 divided into four groups irregularly once the tumor volume reached approximately to  $100 \text{ mm}^3$ . ML141  
184 (#HY-12755, MedChemExpress) was administered in a solution containing PEG300, dimethyl sulfoxide, and PBS  
185 [40/5/55 (v/v/v)]. The mice were then treated intraperitoneally with or without ML141 (30 mg/kg once a day)  
186 and/or 150  $\mu\text{g}/\text{mouse}$  of anti-PD-1 antibody (#-BE0273, Bio X Cell) every other day for one injection. Tumor  
187 volumes were calculated using the formula:  $V = (\text{length} \times \text{width}^2) / 2$ . Body weights and tumor volumes of the mice  
188 were measured daily. The tumor growth inhibition (TGI) value was calculated using the formula:  $\text{TGI} =$   
189  $[1 - \text{Relative Tumor Volume (Treatment)} / \text{Relative Tumor Volume (Vehicle)}] \times 100\%$ .

190

## 191 **Flow cytometry analysis**

192 The tumor tissues were firstly digested into single cells using a digestion solution containing 0.001%  
193 hyaluronidase, 0.1% collagenase, 0.002% DNase, 120  $\mu\text{M}$   $\text{MgCl}_2$ , and 120  $\mu\text{M}$   $\text{CaCl}_2$  in RPMI 1640 medium.  
194 Subsequently, red blood cells were lysed using ammonium chloride for 3 minutes and then the cell samples were  
195 stained with Fixable Viability Stain 700 (#564997, BD). The Fc receptors were blocked with TruStain FcX™  
196 (anti-mouse CD16/32) antibody (#101320, Biolegend) and stained with the following antibodies: APC-Cy7 rat

197 anti-mouse CD45 (#557659, BD), FITC CD3 monoclonal antibody (17A2) (#11-0032-82, Invitrogen), and  
198 Brilliant Violet 421 anti-mouse CD8a antibody (#100738, Biolegend). The stained cells were analyzed using the  
199 Agilent Novocyte 3000 instrument, and all data were analyzed with FlowJo software.

200

## 201 **Results**

### 202 **Mutation in CDC42 gene set was associated with improved clinical outcomes for ICI therapy.**

203 As shown in Fig.1 a, the ORR of patients in the CDC42 gene set mutation group (ORR = 53%, 53/100) was  
204 significantly higher ( $p = 6.59E-7$ ) compared to the CDC42 gene set wild type group (ORR = 26.34%, 123/467).  
205 Additionally, the DCB of patients in the CDC42 gene set mutation group (DCB = 64.21%, 61/95) was also  
206 significantly higher ( $p = 2.12E-5$ ) than the wild type group (DCB = 39.87%, 179/449). Moreover, CDC42 gene set  
207 mutation patients had significantly longer overall survival time ( $p = 2.9E-4$ , HR = 0.52, 95%CI = 0.36-0.75) and  
208 progression-free survival time ( $p = 2.92E-6$ , HR = 0.46, 95%CI = 0.33-0.64) compared to the CDC42 gene set  
209 wild type group.

210


211 We divided the collected ICI therapy dataset into two groups: CDC42 gene set mutation group and CDC42 gene  
212 set wild type group. For each patient group, we sampled 1000 times to further explore ORR's difference in  
213 different CDC42 gene set statuses. The same operation was also performed on DCB. As shown in Fig. 1e, the  
214 mean values distribution of ORR was significantly different between the two patient groups ( $p < 2.22E-16$ ). The  
215 95% confidence interval (CI) was 0.22-0.30, with a standard deviation (STD) was 0.02 in CDC42 gene set wild  
216 type group. In CDC42 gene set mutation group, the 95%CI was 0.43-0.63, and the STD was 0.05. Similarly, in  
217 Fig. 1f, the mean values distribution of DCB was significantly different between the two patient groups ( $p <$   
218  $2.22E-16$ ). The 95%CI was 0.35-0.45, with a STD of 0.024 in CDC42 gene set wild type group. In CDC42 gene  
219 set mutation group, the 95%CI was 0.54-0.74, and the STD was 0.051. Based on these results, it can be inferred

220 that patients with CDC42 gene set mutations are more likely to have clinical benefits from receiving ICI treatment.

221 Overall, the results in Fig. 1 suggest that the CDC42 gene set mutation could serve as a biomarker for the clinical

222 response of ICI treatment.

223



224

225 **Fig.1. Analysis of CDC42 gene set mutation as a biomarker for ICI therapy.** **a**, The differences in ORR between CDC42 gene set  
226 mutation and CDC42 gene set wild type groups. **b**, The differences in DCB between CDC42 gene set mutation and CDC42 gene set  
227 wild type groups. **c**, The KM curve of OS based on the CDC42 gene set status. **d**, The KM curve of PFS based on the CDC42 gene  
228 set status. **e**, The distribution of mean values of ORR based on bootstrap samples. **f**, The distribution of mean values of DCB based  
229 bootstrap samples. ORR, objective response ratio; DCB, durable clinical benefit; KM, Kaplan-Meier; OS, overall survival; PFS,  
230 progression-free survival.

231


### 232 **Assessment of intrinsic immune response landscapes in CDC42 gene set wild type and** 233 **mutation tumors**

234 We initially examined the relationship between CDC42 gene set status and immunogenicity in the ICI therapy  
235 cohort. As shown in Fig. 1a and Fig. 1b, the levels of TMB and NAL in the CDC42 gene set mutation group were  
236 significantly higher than those in the CDC42 gene set wild type group (TMB:  $p < 2.22E-16$ , NAL:  $p = 8.1E-14$ ).  
237 These findings indicate a strong association between CDC42 gene set mutations and increased immunogenicity, as  
238 well as a higher likelihood of positive responses to ICI therapy. We also explored the relationship between CDC42  
239 gene set status and immunogenicity in the TCGA cohort. Compared to CDC42 gene set wild type tumors, both the  
240 nonsilent mutation rate and the silent mutation rate were significantly higher than in CDC42 gene set mutation  
241 tumors ( $p < 2.22E-16$ , Fig.2c, d). Additionally, both SNV neoantigens and indel neoantigens were significantly  
242 more abundant in in CDC42 gene set mutation tumors compared to CDC42 gene set wild type tumors ( $p <$   
243  $2.22E-16$ , Fig.2e, f). These results in the TCGA cohort further support the notion that the CDC42 gene set mutations  
244 are associated with enhanced tumor immunogenicity.

245

246 Then, we investigated the relationship between CDC42 gene set status and the expression of immune-related  
247 molecules, including two class MHC molecules, immune checkpoint, and co-stimulators. We found that immune

248 checkpoint genes PDCD1, CD274 and CTLA-4 were upregulated in the CDC42 gene set mutation group. as  
249 shown in Fig 2h-j. Additionally, we observed significantly higher expression of MHC1, MHC2, other immune  
250 checkpoints (ICPs), and co-stimulators in CDC42 gene set mutation tumors compared to CDC42 gene set wild  
251 type, as shown in Fig. 2g. Previous studies have suggested that higher expression of immune checkpoint-related  
252 genes is indicative of a better response to ICIs therapy[33, 34]. MHC1 plays a crucial role in presenting antigens  
253 to CD8 T cells, and its down-regulation is associated with resistance to ICIs[35]. Moreover, positive expression of  
254 MHC2 correlates with a response to ICIs therapy[36]. Co-stimulators can promote T cell activation and survival,  
255 and activation of co-stimulatory pathways enhances checkpoint inhibition[37, 38]. In summary, these results  
256 demonstrate that CDC42 gene set mutation is a strong predictive biomarker for ICI therapy response.



257

258 **Fig.2. Analysis of intrinsic immune response landscapes in CDC42 gene set wild type and mutation tumors. Comparison of a.**

259 TMB, **b.** NAL between CDC42 gene set wild type and CDC42 gene set mutation groups in the ICI therapy cohort. Comparison of **c.**

260 nonsilent mutation rate, **d.** silent mutation rate, **e.** SNV neoantigens, **f.** indel neoantigens, **g.** expression of MHC and other ICP

261 molecules and costimulators, **h.** expression of PDCD1, **i.** expression of CD274, **j.** expression of CTLA-4 between CDC42 gene set

262 wild type and CDC42 gene set mutation groups in the TCGA cohort. TMB, tumor mutation load; ICI, immune checkpoint inhibitor;

263 NAL, neoantigen load; SNV, single nucleotide variant; ICP, immune checkpoint. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P <$

264 0.0001

265

266 **Assessment extrinsic immune response landscapes in CDC42 gene set wild type and mutation**

267 **tumors**

268 The different situations of immune cell infiltration result in different clinical outcomes of ICI therapy[39].  
269 Therefore, we investigated the difference in tumor microenvironment (TME) between CDC42 gene set wild type  
270 and mutation tumors. This included analyzing immune cell score, signatures representing their function, and  
271 differential gene expression related to immune cell and ICI therapy efficiency.

272


273 As shown in Fig. 3a and 3b, the leukocyte fraction and lymphocyte fraction in CDC42 gene set mutation tumors  
274 were significantly higher than those in CDC42 wild type gene set tumors (leukocyte fraction,  $p = 5.7E-06$ ;  
275 lymphocyte fraction,  $p = 6.3E-06$ ). As TIL is crucial for killing tumors[40], TIL fractions estimated at both  
276 molecular and image levels were compared. Fig. 3c shows that TIL fractions (molecular estimate) in CDC42 gene  
277 set mutation tumors are significantly higher than those in CDC42 gene set wild type tumors ( $p = 9.5E-3$ ). Fig. 3d  
278 shows that TIL fractions (images estimate) in CDC42 gene set mutation tumors are significantly higher than in  
279 those in CDC42 gene set wild type tumors ( $p = 3E-06$ ). These results indicate that CDC42 gene set mutation  
280 tumors are more likely to be recognized and killed by immune cells than CDC42 gene set wild type tumors.

281

282 Cibersort scores based on the TCGA cohort were also compared between CDC42 gene set wild type and mutation  
283 tumors. As shown in Fig. 3e, the percentages of immune cell types were compared in detail. We found significant  
284 differences in most of the immune cell scores between CDC42 gene set wild type and mutation tumors. For  
285 example, the CD8 T cell and macrophage M1 cell scores in the CDC42 gene set mutation type were significantly  
286 higher than that in the CDC42 gene set wild type tumors. These findings are consistent with previous reports that  
287 CD8 T cell are key determinants of response to ICI, and macrophage M1 cells are related to T cell stimulation and  
288 ICI therapy[34, 41]. Fig. 3f shows ssGSEA results based on 29 immune signatures. We found that CD8 T cell and  
289 checkpoint signatures in CDC42 gene set mutation type tumors were significantly higher than those in CDC42



290 gene set wild type tumors. These results are also consistent with previous reports that CD8 T cells are key  
 291 determinants of response to ICI and higher expression of immune checkpoint-related genes is more likely to  
 292 benefit clinically from ICIs treatment[33]. Fig. 4a further shows that immune signatures were significantly  
 293 enriched in CDC42 gene set mutation tumors compared to CDC42 gene set wild type tumors.




295 **Fig.3. Analysis of extrinsic immune response landscapes of CDC42 gene set wild type and CDC42 gene set mutation tumors in**  
296 **the TCGA cohort.** Comparison of **a.** leukocyte fraction, **b.** lymphocyte fraction, **c.** TIL fraction based on molecular estimates, **d.** TIL  
297 fraction based on images estimates, **e.** immune cell infiltration, **f.** 29 immune signatures estimated through the ssGSEA method  
298 between CDC42 gene set wild type and CDC42 gene set mutation tumors. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001

299

300 We further conducted GSEA analysis, as well as expression analysis of chemokines and chemokines receptors,  
301 interleukins and interleukins receptors, TCR, and cytolytic activity score based on CDC42 gene set status. In Fig.  
302 4b, we observed enrichment of base excision repair, homologous recombination, mismatch repair pathway  
303 enriched in CDC42 gene set mutation tumors, while fatty acid degradation and Ras signaling pathway were  
304 enriched in CDC42 gene set wild type tumors. These results align well with previous reports. For example, Jiang  
305 et al reported that DDR pathways are associated with the response to ICIs treatment[42]. Ward et al reported that  
306 activation of the Ras signaling pathway leads to an immunosuppressive tumor microenvironment, hindering T  
307 cells activation and infiltration, thus affecting the therapeutic efficacy of ICI[43]. Li et al reported that increased  
308 lipid content is correlated with a favorable ICI response[44], suggesting that higher lipid accumulation may  
309 indicate a higher likelihood of a positive response to ICI therapy. In Fig. 4c, we found a higher TCR Shannon  
310 score in CDC42 gene set mutation tumors compared to that in CDC42 gene set wild tumors ( $p = 2.9E-3$ ). Higher  
311 TCR diversity may indicate that T cells can recognize more neoantigens, and studies have shown that patients  
312 with higher TCR diversity scores have more favorable clinical responses to ICI treatment[45]. The cytolytic  
313 activity score in CDC42 gene set mutation patients was significantly higher than in CDC42 gene set wild type  
314 patients (Fig.4d,  $p < 2.22E-16$ ). CYT is upregulated during T cell activation[46], indicating that upregulated CYT  
315 leads to more effective tumor killing. As shown in Fig. 5e, most chemokines in CDC42 gene set mutation patients  
316 were significantly higher than in CDC42 gene set wild type patients. Previous studies have reported that CXCL9,  
317 CXCL10 and CXCL11 can enhance T cell infiltration, thereby improving the therapeutic efficacy of ICI

318 interventions[47-49]. The expression of CXCL13 can generate effector T cells and is closely associated with the  
319 response to ICIs treatment[50]. There were also significant differences in interleukins and interleukins receptors  
320 expression between CDC42 gene set statuses, consistent with previous study reports. Pegilodecakin (PEGylated  
321 recombinant IL-10) induces the proliferation of CD8 T cells both within the tumor microenvironment and in the  
322 systemic circulation, while also activating CD8 T cells within TME[51]. IL-21 functions as a robust survival  
323 factor for both natural killer (NK) and T cells, while also inhibiting the differentiation of Tregs[52]. Therefore, the  
324 significantly high expression of IL-10 and IL-21 in CDC42 gene set mutation patients may indicate the presence  
325 of more CD8 T cells in TME and a higher probability of a positive response to ICI therapy compared to patients  
326 with CDC42 gene set wild type status. Moreover, the association of IL-33 with the establishment of a tumorigenic  
327 niche has been reported[53], suggesting that its elevated expression in CDC42 wild type patients might imply a  
328 reduced likelihood of responding to ICI therapy. Overall, through the above analyses, we observed enhanced  
329 immunity and a greater probability response to ICI in CDC42 gene set mutation patients compared to CDC42  
330 gene set wild type patients.



331

332 **Fig.4. Analysis of gene expression related to immune cell between CDC42 gene set wild type and CDC42 gene set mutation**

333 **tumors in the TCGA cohort. a, Volcano plots showing the analysis of 29 immune signatures estimated by the ssGSEA method for**

334 **CDC42 gene set wild type and CDC42 gene set mutation tumors. b, GSEA analysis results based on CDC42 gene set status, with**

335 **gene sets having an FDR (Benjamini-Hochberg method) lower than 0.25 considered significantly enriched. c, Comparison of the**


336 **TCR Shannon score between CDC42 gene set wild type and CDC42 gene set mutation tumors. d, Comparison of the cytolitic**

337 activity score between CDC42 gene set wild type and CDC42 gene set mutation tumors. e, Comparison of the chemokines (and  
338 receptors) and interleukins (and receptors) between CDC42 gene set wild type and CDC42 gene set mutation tumors. \*P < 0.05, \*\*P  
339 < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001.

340

### 341 **Exploring the synergy of CDC42 inhibitor in combination with ICI to enhance** 342 **immunotherapy efficacy**

343 We investigated the antitumor effect of combining a CDC42 inhibitor (ML141) with anti-PD-1 antibody.  
344 Treatment with anti-PD-1 antibody alone demonstrated ordinary therapeutic capacity, with a TGI of 38% (Fig. 5a).  
345 Treatment with ML141 alone resulted in a TGI of 63% (Fig. 5a). Notably, the combination of ML141 and  
346 anti-PD-1 antibody significantly reduced tumor growth (TGI = 86%) and prolonged survival time compared to the  
347 anti-PD-1 antibody alone group (Fig. 5a and 5b). This suggests that the combination therapy can effectively exert  
348 potent antitumor immune activity. Furthermore, these treatments did not lead to weight loss in the mice (Fig. 5c),  
349 indicating that this dosing regimen is safe. To determine the role of the immune response in the antitumor activity  
350 of this dosage regimen, we analyzed the immune cells' infiltration in the TME using flow cytometry experiments.  
351 The results showed that a combination of ML141 and an anti-PD-1 antibody significantly increased the frequency  
352 of CD45+ lymphocytes, CD3+ T cells, and CD8+ cytotoxic T cells in the TME compared to the anti-PD-1  
353 antibody alone (Fig. 5d-f, Fig. S1). Furthermore, the use of ML141 alone also raised the frequency of CD3+ T  
354 cells and CD8+ cytotoxic T cells in the TME, aligning with earlier discoveries that the pharmacological inhibition  
355 of CDC42 triggers antitumor immune activity[4]. Interestingly, the CDC42 inhibitor mimics the defective  
356 function of CDC42 to a certain degree. As a result, our experiment confirms that the defective function of CDC42  
357 is a biomarker for ICI therapy. Overall, these findings suggest that CDC42 inhibitor, used in conjunction with ICI,  
358 has a synergistic therapeutic effect and can enhance the efficacy of immunotherapy.



359

360

**Fig. 5 ML141 enhances Anti-PD-1 antibody induced tumor inhibition *in vivo*.** **a**, Growth curves of tumors from the indicated

361

groups (n = 8). **b**, Kaplan-Meier survival curves of mice in the indicated group (n = 8). **c**, Body weight change curves of mice in the

362

indicated group. **d-f**, Impact of Anti-PD-1 antibody alone, ML141 alone, or a combination of both on the frequency of CD45<sup>+</sup>

363

lymphocytes, CD3<sup>+</sup> T cells, and CD8<sup>+</sup> T cells in TEM, assessed by flow cytometry. Error bars represent mean ± SEM; statistical

364

analysis by Wilcoxon rank sum test (a) or logrank test (b) or two-tailed unpaired t-test (d-f). \*, P < 0.05; \*\*, P < 0.01; ns, no

365

statistical difference, P > 0.05.

366

367

## Discussion

368

CDC42 downstream signals are known to be involved in stimulating tumors, including tumorigenesis, progression,

369 invasion, and metastasis[3]. The purpose of this study is to investigate whether the defective function of CDC42  
370 could be used as a biomarker for ICI therapy. We hypothesized that CDC42's function may not only depend on  
371 CDC42 itself but also on its binding protein and effector protein. These genes are collectively referred to as the  
372 CDC42 gene set. Mutations in the CDC42 gene set genes may result in the partial defectiveness of CDC42  
373 function. By analyzing a dataset of patients undergoing ICI treatment, we observed that patients with CDC42 gene  
374 set mutations had a higher rate of ORR and DCB. Additionally, these patients showed significantly longer OS and  
375 PFS time compared to patients with wild type CDC42 gene set genes. Bootstrap samples further confirmed that  
376 patients with CDC42 gene set mutations are more likely to respond to ICIs than patients with wild type CDC42  
377 gene set genes. These analyses indicate that CDC42 gene set mutation can serve as a clinical biomarker for ICI  
378 therapy. In animal experiments, employing CDC42 inhibitors to mimic the defective function of CDC42 resulting  
379 in improved survival times in mice that were initially insensitive to anti-PD-1 treatment. This finding further  
380 validates the utility of the defective function of CDC42 as a potential biomarker for ICI treatment to some extent.

381

382 We conducted a further analysis of the CDC42 gene set's status to better understand its role in indicating the  
383 clinical response to ICI using the TCGA dataset. Our findings revealed that tumors with CDC42 gene set  
384 mutations exhibited stronger immunogenicity, as evidenced by higher TMB and NAL. Additionally, we compared  
385 the gene expression levels of MHC1, TCR Shannon, and CYT, and observed significantly higher expression levels  
386 of these genes in patients with CDC42 gene set mutations. MHC1 plays a crucial role in presenting antigens to  
387 CD8 T cells, and its down-regulation has been associated with resistance to ICI[35]. Moreover, elevated level of  
388 TCR diversity and high expression of CYT indicate T cell activation and enhanced tumor cell killing efficiency. In  
389 summary, these comparisons highlight a more active immune response in CDC42 gene set mutation patients,  
390 characterized by stronger immunogenicity and the potential for more effective T cell activation and killing  
391 through increased MHC1 antigen presentation and TCR diversity, as well as higher CYT expression.

392

393 In TME, leukocyte fraction, lymphocyte fraction, TIL fraction and CD8 T cell levels were substantially higher in  
394 patients with CDC42 gene set mutations compared to those with CDC42 gene set wild type, indicating enhanced  
395 immunity. The increased expression of chemokines, such as CXCL9, CXCL10 and CXCL11, in patients with  
396 CDC42 gene set mutations can recruit more T cells into TME[47-49]. Additionally, higher expression of  
397 interleukins, like IL-10 and IL-21, in CDC42 gene set mutation patients promotes the survival of T cells. These  
398 findings suggest that CDC42 gene set mutation patients have a TME with increased infiltration of immune cell,  
399 particularly CD8 T cells, which experience improved survival conditions. Studies have shown that CD8 T cells  
400 play a critical role in eliminating tumors, and their presence within the tumor microenvironment is associated with  
401 better clinical responses to ICI treatments[34]. Furthermore, elevated expression of ICPs has been linked to  
402 positive responses to ICI treatments[33]. Therefore, the utilization of ICI therapies in patients with CDC42 gene  
403 set mutations (who exhibit elevated expression of ICPs) may potentially restore the suppressed function of CD8 T  
404 cells. In summary, the aforementioned analyses collectively highlight the significance of considering CDC42 gene  
405 set mutations as a potential biomarker for predicting responses to ICI treatment.

406

407 Some other biomarkers for ICI treatment, such as NOTCH4[54] and PAPP2[55], do not indicate whether their  
408 biomarker function come from the alternation of their function, and the potential for combining their inhibitors  
409 with ICI was not examined. We hypothesize that the function of CDC42 may not only depend on itself but also its  
410 downstream binding protein and effector function. Mutations in CDC42 gene set result in the defective function of  
411 CDC42 and inhibition of tumor growth, which further releases immune suppression. Therefore, the functional  
412 defectiveness in CDC42 may underlie its potential as a biomarker for clinical benefit from ICI therapy. The  
413 significant difference between mutations in CDC42, its downstream binding proteins and effector proteins and the  
414 clinical benefit of ICI partially confirms our hypothesis. Hence, we propose that the combined use of ICI and



415 CDC42 inhibitors could further enhance ICI's efficacy, and we conducted experiment exploration. Animal  
416 experiment data demonstrated that the ML141 inhibitor indeed could further promote ICI's efficacy, further  
417 confirming our hypothesis and providing valuable insights for further exploration in clinical settings.

418

## 419 **Conclusion**

420 In conclusion, we have speculated that CDC42's function may depend not only on CDC42 itself but also its  
421 binding proteins and effector proteins. We have also demonstrated that mutations in the CDC42 gene set could  
422 serve as a novel biomarker for predicting the clinical response of ICI therapy. Furthermore, the analysis of the  
423 TCGA dataset and the animal experiment further supports the role of this predictive biomarker. Additionally, this  
424 study has provided insight into the potential synergistic effects of combining CDC42 inhibitors with ICIs to  
425 enhance their efficacy, especially bringing hope to situations that failed to respond to anti-PD-1 treatment. Our  
426 study introduces a novel approach to biomarker analysis, considering that changes in the function of a key gene  
427 can result from mutations in downstream effector proteins as well. Analyzing gene sets collectively like this may  
428 facilitate the discovery of new biomarkers and potential drug targets.

429

## 430 **Abbreviations**

431 CI: confidence interval; CR: complete response; CTLA-4: cytotoxic T lymphocyte-associated protein-4; CYT:  
432 cytolytic activity; DCB: Durable clinical benefit; GSEA: gene set enrichment analysis; GZMA: granzyme A; HCC:  
433 hepatocellular carcinoma; HR: hazard ratio; ICIs: immune checkpoint inhibitors; ICP: immune checkpoint; KEGG:  
434 Kyoto Encyclopedia of Genes and Genomes; KM: Kaplan-Meier; NAL: neoantigen load; NE: non-evaluable; NR:  
435 non-responder; ORR: objective response rate; OS: overall survival; PD: progressive disease; PD-1: Programmed  
436 Death Receptor 1; PFS: progression-free survival; PFS: progression-free survival; PR: partial response; PRF1:  
437 perforin 1; R: responder; Rho: ras homologous; SD: stable disease; SNV: single nucleotide variation; ssGSEA:

438 single-sample gene set enrichment analysis; STD: standard deviation; TCGA: The Cancer Genome Atlas; TCGA:  
439 The Cancer Genome Atlas; TIL: tumor-infiltrating lymphocyte; TMB: tumor mutational burden; TME: tumor  
440 microenvironment; Tregs: regulatory T cells; VEGF: vascular endothelial growth factor; WES: whole exome  
441 sequencing

442

## 443 **Declarations**

444

## 445 **Ethics approval and consent to participate**

446 Not applicable.

## 447 **Consent for publication**

448 Not applicable.

## 449 **Availability of data and materials**

450 The datasets supporting the conclusions of this article are included within the article.

## 451 **Competing interests**

452 The authors declare that they have no competing interests.

## 453 **Funding**

454 We gratefully acknowledge financial support from National Natural Science Foundation of China (T2225002,  
455 82273855 to M.Y.Z.), SIMM-SHUTCM Traditional Chinese Medicine Innovation Joint Research Program  
456 (E2G805H), Shanghai Municipal Science and Technology Major Project, National Key Research and  
457 Development Program of China (2022YFC3400504 to M.Y.Z.), the Youth Innovation Promotion Association CAS  
458 (2023296 to S.L.Z.) and the Natural Science Foundation of Shanghai (22ZR1474300 to S.L.Z.).

## 459 **Authors' contributions**

460 M.Y.Z, S.L.Z, K.W and Y.Y. Zhang conceived of and designed the study. K.W and Y.Y. Zhang drafted the

461 manuscript. K.W conducted the data analysis. Y.Y. Zhang and Z.M.S performed the experiments. C.Y.X provided  
462 administrative support. B.W, Y.Y. Zhou, X.C.T and X.M.L participated in the discussion. All authors read and  
463 approved the final version of the manuscript and are accountable for all aspects of the work.

## 464 **Acknowledgements**

465 The authors would like to acknowledge their colleague, mentor, and friend, Dr. Hualiang Jiang (1965–2022), who  
466 took part in the work and in the preparation of the original manuscript.

467

## 468 **Reference**

- 469 1. Sharma, P., et al., *Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy*. Cell, 2017.  
470 **168**(4): p. 707-723.
- 471 2. *Cancer immunotherapy: the quest for better biomarkers*. Nat Med, 2022. **28**(12): p. 2437.
- 472 3. Xiao, X.H., et al., *Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and*  
473 *MicroRNA as New Treatment Candidates*. Molecules, 2018. **23**(4).
- 474 4. Kalim, K.W., et al., *Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell*  
475 *immunity*. J Immunother Cancer, 2022. **10**(11).
- 476 5. Xu, J., et al., *Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage*  
477 *with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes*. Clin Res  
478 Hepatol Gastroenterol, 2023. **47**(7): p. 102149.
- 479 6. Guo, L., et al., *Serum cell division cycle 42 reflects the treatment response and survival in patients*  
480 *with advanced cervical cancer who receive immune checkpoint inhibitor treatment*. Oncol Lett, 2023.  
481 **26**(3): p. 414.
- 482 7. De Henau, O., et al., *Overcoming resistance to checkpoint blockade therapy by targeting*  
483 *PI3Kgamma in myeloid cells*. Nature, 2016. **539**(7629): p. 443-447.

- 484 8. Chen, H.Y., et al., *Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation*  
485 *capacity and tamoxifen sensitivity in basal-like breast cancer cells*. EMBO Mol Med, 2013. **5**(5): p.  
486 723-36.
- 487 9. Miao, D., et al., *Genomic correlates of response to immune checkpoint therapies in clear cell renal*  
488 *cell carcinoma*. Science, 2018. **359**(6377): p. 801-806.
- 489 10. Hugo, W., et al., *Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in*  
490 *Metastatic Melanoma*. Cell, 2016. **165**(1): p. 35-44.
- 491 11. Riaz, N., et al., *Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab*. Cell,  
492 2017. **171**(4): p. 934-949 e16.
- 493 12. Miao, D., et al., *Genomic correlates of response to immune checkpoint blockade in*  
494 *microsatellite-stable solid tumors*. Nat Genet, 2018. **50**(9): p. 1271-1281.
- 495 13. Rizvi, N.A., et al., *Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade*  
496 *in non-small cell lung cancer*. Science, 2015. **348**(6230): p. 124-8.
- 497 14. Snyder, A., et al., *Genetic basis for clinical response to CTLA-4 blockade in melanoma*. N Engl J Med,  
498 2014. **371**(23): p. 2189-2199.
- 499 15. Van Allen, E.M., et al., *Genomic correlates of response to CTLA-4 blockade in metastatic melanoma*.  
500 Science, 2015. **350**(6257): p. 207-211.
- 501 16. Hellmann, M.D., et al., *Genomic Features of Response to Combination Immunotherapy in Patients*  
502 *with Advanced Non-Small-Cell Lung Cancer*. Cancer Cell, 2018. **33**(5): p. 843-852 e4.
- 503 17. Liu, D., et al., *Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in*  
504 *patients with metastatic melanoma*. Nat Med, 2019. **25**(12): p. 1916-1927.
- 505 18. Zhang, Z., et al., *EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in*  
506 *multiple cancers*. BMC Med, 2021. **19**(1): p. 26.

- 507 19. Colaprico, A., et al., *TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data*.  
508 *Nucleic Acids Res*, 2016. **44**(8): p. e71.
- 509 20. Liu, J., et al., *An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival*  
510 *Outcome Analytics*. *Cell*, 2018. **173**(2): p. 400-416 e11.
- 511 21. Thorsson, V., et al., *The Immune Landscape of Cancer*. *Immunity*, 2018. **48**(4): p. 812-830 e14.
- 512 22. Villaruz, L.C. and M.A. Socinski, *The clinical viewpoint: definitions, limitations of RECIST, practical*  
513 *considerations of measurement*. *Clin Cancer Res*, 2013. **19**(10): p. 2629-36.
- 514 23. Rizvi, H., et al., *Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and*  
515 *Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer*  
516 *Profiled With Targeted Next-Generation Sequencing*. *J Clin Oncol*, 2018. **36**(7): p. 633-641.
- 517 24. Saltz, J., et al., *Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes*  
518 *Using Deep Learning on Pathology Images*. *Cell Rep*, 2018. **23**(1): p. 181-193 e7.
- 519 25. He, Y., et al., *Classification of triple-negative breast cancers based on Immunogenomic profiling*. *J*  
520 *Exp Clin Cancer Res*, 2018. **37**(1): p. 327.
- 521 26. Hänzelmann, S., R. Castelo, and J. Guinney, *GSVA: gene set variation analysis for microarray and*  
522 *RNA-seq data*. *BMC bioinformatics*, 2013. **14**: p. 1-15.
- 523 27. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and dispersion for*  
524 *RNA-seq data with DESeq2*. *Genome Biol*, 2014. **15**(12): p. 550.
- 525 28. Yu, G., et al., *clusterProfiler: an R package for comparing biological themes among gene clusters*.  
526 *OMICS*, 2012. **16**(5): p. 284-7.
- 527 29. Rooney, M.S., et al., *Molecular and genetic properties of tumors associated with local immune*  
528 *cytolytic activity*. *Cell*, 2015. **160**(1-2): p. 48-61.
- 529 30. Ruiz-Bañobre, J., et al., *Rethinking prognostic factors in locally advanced or metastatic urothelial*

- 530            *carcinoma in the immune checkpoint blockade era: a multicenter retrospective study*. ESMO open,  
531            2021. **6**(2): p. 100090.
- 532    31.    Bland, J.M. and D.G. Altman, *The logrank test*. Bmj, 2004. **328**(7447): p. 1073.
- 533    32.    Virtanen, P., et al., *SciPy 1.0: fundamental algorithms for scientific computing in Python*. Nat Methods,  
534            2020. **17**(3): p. 261-272.
- 535    33.    Hu, F.F., et al., *Expression profile of immune checkpoint genes and their roles in predicting*  
536            *immunotherapy response*. Brief Bioinform, 2021. **22**(3).
- 537    34.    Oba, T., et al., *Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and*  
538            *activation of tumor-residing cDC1s*. Nat Commun, 2020. **11**(1): p. 5415.
- 539    35.    Luo, N., et al., *DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T*  
540            *lymphocyte responses in breast cancer*. Nat Commun, 2018. **9**(1): p. 248.
- 541    36.    Johnson, D.B., et al., *Melanoma-specific MHC-II expression represents a tumour-autonomous*  
542            *phenotype and predicts response to anti-PD-1/PD-L1 therapy*. Nat Commun, 2016. **7**: p. 10582.
- 543    37.    Chen, L. and D.B. Flies, *Molecular mechanisms of T cell co-stimulation and co-inhibition*. Nature  
544            Reviews Immunology, 2013. **13**(4): p. 227-242.
- 545    38.    Jeong, S. and S.H. Park, *Co-Stimulatory Receptors in Cancers and Their Implications for Cancer*  
546            *Immunotherapy*. Immune Netw, 2020. **20**(1): p. e3.
- 547    39.    Liu, R., et al., *Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic*  
548            *Efficacy: A Computational Retrospective Study*. Front Immunol, 2021. **12**: p. 685370.
- 549    40.    Li, B., *Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?*  
550            Front Immunol, 2022. **13**: p. 973881.
- 551    41.    Zhang, H., et al., *Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for*  
552            *solid cancers*. Mol Cancer, 2023. **22**(1): p. 58.

- 553 42. Jiang, M., et al., *Alterations of DNA damage response pathway: Biomarker and therapeutic strategy*  
554 *for cancer immunotherapy*. Acta Pharm Sin B, 2021. **11**(10): p. 2983-2994.
- 555 43. Ward, A.B., et al., *Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS*.  
556 MedComm (2020), 2020. **1**(2): p. 121-128.
- 557 44. Li, X., et al., *Navigating metabolic pathways to enhance antitumour immunity and immunotherapy*.  
558 Nature Reviews Clinical Oncology, 2019. **16**(7): p. 425-441.
- 559 45. Ma, W., B. Pham, and T. Li, *Cancer neoantigens as potential targets for immunotherapy*. Clin Exp  
560 Metastasis, 2022. **39**(1): p. 51-60.
- 561 46. Johnson, B.J., et al., *Single-cell perforin and granzyme expression reveals the anatomical localization*  
562 *of effector CD8+ T cells in influenza virus-infected mice*. Proceedings of the National Academy of  
563 Sciences, 2003. **100**(5): p. 2657-2662.
- 564 47. Peng, D., et al., *Epigenetic silencing of TH1-type chemokines shapes tumour immunity and*  
565 *immunotherapy*. Nature, 2015. **527**(7577): p. 249-53.
- 566 48. Reschke, R. and T.F. Gajewski, *CXCL9 and CXCL10 bring the heat to tumors*. Science immunology,  
567 2022. **7**(73): p. eabq6509.
- 568 49. Li, Y., et al., *CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy:*  
569 *A Pan-Cancer Analysis*. Front Immunol, 2022. **13**: p. 951247.
- 570 50. Hsieh, C.H., et al., *Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor*  
571 *Treatment in Cancer*. Cancers (Basel), 2022. **14**(2).
- 572 51. Tannir, N.M., et al., *Pegilodexakin as monotherapy or in combination with anti-PD-1 or tyrosine*  
573 *kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of*  
574 *cohorts A, G, H and I of IVY Phase I study*. Int J Cancer, 2021. **149**(2): p. 403-408.
- 575 52. Mortezaee, K. and J. Majidpoor, *Checkpoint inhibitor/interleukin-based combination therapy of cancer*.

576 Cancer Med, 2022. 11(15): p. 2934-2943.

577 53. Briukhovetska, D., et al., *Interleukins in cancer: from biology to therapy*. Nat Rev Cancer, 2021. 21(8):  
578 p. 481-499.

579 54. Long, J., et al., *Identification of NOTCH4 mutation as a response biomarker for immune checkpoint*  
580 *inhibitor therapy*. BMC Med, 2021. 19(1): p. 154.

581 55. Dong, Y., et al., *PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint*  
582 *inhibitors in skin cutaneous melanoma and non-small cell lung cancer*. Cell Prolif, 2022: p. e13283.

583